Navigation Links
Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis
Date:6/13/2013

tal Sciences in the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences at the University of Oxford, and steering committee member for the study.

A copy of the EULAR oral presentation can be accessed at:  2013 EULAR - JADA 52-Week Presentation  

Trial DesignThis randomized, open-label, long-term extension of Phase 2b JADA study included 201 (95 percent) of the eligible 212 patients. Of the 201 patients, 184 completed 52 weeks of treatment, 15 discontinued treatment, and two patients had not yet completed the full 52 weeks of treatment. Patients received either 4 mg or 8 mg once-daily doses of baricitinib beginning at week 24 through week 52.

In the initial 12-week treatment duration, patients received one of four doses of baricitinib (1 mg, 2 mg, 4 mg or 8 mg) or placebo, administered once daily. In the 12- to 24-week portion of the study, patients initially randomized to placebo or the 1 mg baricitinib dose were re-randomized to receive either 4 mg once daily or 2 mg twice daily for an additional 12 weeks; patients initially randomized to the 2 mg, 4 mg and 8 mg doses continued therapy with those doses.

Patients who completed week 24 were eligible to receive either the 4- or 8-mg once daily dose through week 52. The study is ongoing, with all patients who are continuing in the study receiving baricitinib 4 mg once daily.

About JAK InhibitionThere are four known JAK enzymes: JAK1, JAK2, JAK3 and TYK2.[3] These enzymes are critical components of signaling mechanisms used by a number of cytokines and growth factors, including several that are elevated in patients with RA. Cytokines such as interleukin-6, -12 and -23 and both type 1 and type 2 interferons signal through these pathways. JAK-dependent cytokines have been implicated in the pathogenesis of a number of inflammatory and autoi
'/>"/>

SOURCE Eli Lilly and Company; Incyte Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Lilly to Present at Goldman Sachs Global Healthcare Conference
2. Lilly Acquires Novel Tau Tangle Diagnostic Program to Bolster Alzheimers Disease Research and Development
3. Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis
4. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff Deadline
5. Todays Research on Incyte and Arena Pharma: Biotech Stocks Up on Drug Approvals
6. Steep Hill Laboratories and Halent Scientific Proudly Announce Historic Merger
7. Andain Inc. Announces 2,000 Units Initial Production of the Breakthrough Miniature Disposable Insulin Pump for Use in Clinical Trials for Type-I and Type-II Diabetes
8. Verenium Announces Appointment Of Brian Carter As Vice President Of Grain Processing
9. Neogen announces Bohannon retirement, successor named
10. BioDelivery Sciences Announces NDA Submission for BUNAVAIL on Track Following Positive Pre-NDA Meeting with FDA
11. Hemostemix Announces Formation of Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Rochelle, N.Y. (PRWEB) August 21, 2014 ... is the first private college in the Mid-Hudson Region ... College will now begin accepting applications from qualified “high-technology” ... , “We are very pleased to have been selected ... support Governor Cuomo’s transformative initiative to stimulate economic development ...
(Date:8/21/2014)... , Aug. 21, 2014 Mathematic studies at ... Harvard University , and funded by the Jeffrey Epstein ... within tumors can be visually identified for elimination. These aggressive ... The study, which shows a topological map of what to ... in cancer research, for while tumor cells can be extracted ...
(Date:8/21/2014)... Aug. 21, 2014  China Cord Blood Corporation (NYSE: ... to release financial results for the first quarter of ... market close in the US.  The ... ET on Friday, August 29, 2014 to discuss its ... Company,s recent developments, followed by a question and answer ...
(Date:8/21/2014)... 2014 Pursuit Solutions ( http://www.pursuit-solutions.com ... and services for Life Sciences sales and marketing ... of New Commercial Sales Models” by Peter Robinson, ... The article examines some innovative models used to ... tested in the pharmaceutical market. Robinson grades the ...
Breaking Biology Technology:The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2
... June 7, 2011 DuPont (NYSE: DD ... investors at the JPMorgan Diversified Industries Conference to expect ... innovation, selective investment in attractive areas, broad-based growth, especially ...  Kullman also reaffirmed DuPont,s 2011 earnings per share (EPS) ...
... its origins in Hamburg. Jrg Weimller, a materials scientist ... Helmholtz Center Geesthacht, has carried out research on this ... Institute for Metal Research in Shenyang, China., The 51-year-old ... which opens the door to a multitude of diverse ...
... of Academic Health Centers (AAHC) supports the Department ... Rights, (OCR) proposed rule, issued last week, furthering ... efforts to alleviate unnecessary compliance and administrative burdens ... placed on covered entities, and applauds its efforts ...
Cached Biology Technology:DuPont Chair & CEO: Delivering Innovative Solutions and Long-term Growth 2DuPont Chair & CEO: Delivering Innovative Solutions and Long-term Growth 3Hard or soft: At the touch of a button 2Hard or soft: At the touch of a button 3AAHC Commends HHS Office for Civil Rights HIPAA Privacy Proposal 2
(Date:8/21/2014)... Nxt-ID, Inc. (OTCQB: NXTD), a biometric authentication ... today that its shares of common stock and the ... its proposed underwritten public offering of common stock and ... Capital Market, subject to closing of its proposed underwritten ... will trade under the symbol "NXTD" and "NXTDW," respectively. ...
(Date:8/21/2014)... Bacteria growing in near darkness use a previously unknown ... a research team led by a Penn State University ... further research aimed at improving plant growth, harvesting energy ... now occurring on Lake Erie and other lakes worldwide. ... the Science Express edition of the journal ...
(Date:8/21/2014)... might seem easy to ignore, but they are the ... depend upon. Humans are increasingly dependent on algae, too, ... and sink it to the bottom of the ocean. ... laboratory experiments, researchers have evidence showing that viruses infecting ... algae,s blooms, even when all else stays essentially the ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3Viruses take down massive algal blooms, with big implications for climate 2
... the University of York have played a crucial role ... up land contaminated by explosives. , The research, by ... (Centre for Novel Agricultural Products) in the University's Department ... trees and plants into highly-effective pollution-busters. The research findings ...
... can harm the brain immediately after a stroke may actually ... the study could change the way stroke is treated, extending ... to a couple of weeks. The results may suggest new ... team from the Harvard Medical School Departments of Radiology and ...
... Medical Center researchers Massimo Trucco, MD, and Nick Giannoukakis, ... model by a novel treatment strategy involving specific modification ... in animal studies. , The U.S. Food and Drug ... to evaluate the safety and feasibility of the treatment ...
Cached Biology News:York researchers develop pollution-busting plants to clean up contaminated land 2'Bad' enzymes may wear white hats after stroke 2'Bad' enzymes may wear white hats after stroke 3'Bad' enzymes may wear white hats after stroke 4Researchers reverse juvenile diabetes in animal model 2Researchers reverse juvenile diabetes in animal model 3Researchers reverse juvenile diabetes in animal model 4
Acetylcholinesterase (human brain, AChE)...
... Microsomal vesicles are used to study ... proteins. Processing events such as signal ... core glycosylation can be examined by ... in vitro in the presence of ...
Polio component type I...
Glucagon-like peptide-1 (GLP-1 (1-36) amide)...
Biology Products: